Suppr超能文献

标准治疗后复发和难治性多发性骨髓瘤患者接受 idecabtagene vicleucel 治疗后的心脏事件。

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.

机构信息

Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, FL.

Department of Cardio-Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.

出版信息

Blood Adv. 2023 Aug 22;7(16):4247-4257. doi: 10.1182/bloodadvances.2023009766.

Abstract

Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, λ light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (≥grade 2) cytokine release syndrome (CRS) and immune cell-associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.

摘要

伊达珠单抗(ide-cel)是一种 B 细胞成熟抗原(BCMA)靶向嵌合抗原受体 T 细胞(CAR-T),获批用于治疗复发/难治性多发性骨髓瘤(RRMM)。目前,与 ide-cel 相关的心脏事件发生率尚不清楚。这是一项针对接受 ide-cel 治疗 RRMM 的患者的回顾性单中心观察性研究。我们纳入了所有接受标准 care ide-cel 治疗并至少随访 1 个月的连续患者。根据心脏事件的发生情况,检查了基线临床危险因素、安全性概况和反应。共对 78 例患者进行了 ide-cel 治疗,11 例(14.1%)发生了心脏事件:心力衰竭(5.1%)、心房颤动(10.3%)、非持续性室性心动过速(3.8%)和心血管死亡(1.3%)。仅有 78 例患者中的 11 例进行了重复超声心动图检查。与心脏事件发生相关的基线危险因素包括女性、较差的表现状态、λ 轻链疾病和晚期修订后的国际分期系统分期。基线心脏特征与心脏事件无关。在 CAR-T 后住院期间,更高等级(≥2 级)细胞因子释放综合征(CRS)和免疫细胞相关神经综合征与心脏事件相关。在多变量分析中,心脏事件与总生存期(OS)和无进展生存期(PFS)相关的风险比分别为 2.66 和 1.98。RRMM 的 ide-cel CAR-T 与其他类型的 CAR-T 具有相似的心脏事件。较差的基线表现状态和更高等级的 CRS 和神经毒性与 BCMA 靶向 CAR-T 细胞治疗后的心脏事件相关。我们的结果表明,心脏事件的存在可能导致更差的 PFS 或 OS;尽管由于样本量小,检测关联的能力有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5d8/10424134/264b4e1913a7/BLOODA_ADV-2023-009766-ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验